Literature DB >> 25284346

Radiation exposure to comforters and carers during paediatric molecular radiotherapy.

J E Gains1, C Walker1, T M Sullivan2, W A Waddington3, N L Fersht1, K P Sullivan1, E Armstrong1, D P D'Souza2, M D Aldridge3, J B Bomanji3, M N Gaze1.   

Abstract

BACKGROUND: To show whether the incidental radiation exposure received by comforters and carers of children undergoing molecular radiotherapy was kept as low as reasonably achievable and was within English national dose constraints. PROCEDURE: The radiation exposure of adult comforters and carers was routinely monitored with a whole body personal dose meter while the child was in hospital. Data were collected on iodine-131 meta-iodobenzylguanidine (131 I-mIBG), lutetium-177 DOTATATE (177 Lu-DOTATATE), and iodine-131 sodium iodide (131 I-NaI) treatments.
RESULTS: Data were available for 50 treatments with high-administered activity double-infusion 131 I-mIBG and 12 single administrations; 15 177 Lu-DOTATATE treatments and 28 131 I-NaI administrations. The median age was 7 years (1-18). The median administered activity of: 131 I-mIBG was 16.2 GBq (6.8-59 GBq) for double infusion patients and 8.1 GBq (5.26-16.25 GBq) for single administrations; 177 Lu-DOTATATE was 7.2 GBq (2.5-7.5 GBq); and 131 I-NaI was 3 GBq for thyroid remnant ablation and 5.5 GBq for cancer therapy. The median number of comforters and carers for all administrations was 2 (range 1-9). The median exposure values for comforters and carers for high-administered activity 131 I-mIBG administrations was 302 µSv (0-5282 µSv); for single fraction 131 I-mIBG 163 µSv (3-3104 µSv); 177 Lu-DOTATATE 6 µSv (1-79 µSv); and 131 I-NaI 37 µSv (0-274 µSv). Only one of the comforters and carers exceeded the dose constraint of 5 mSv.
CONCLUSIONS: Doses to comforters and carers were in all but one case within the dose constraint nationally recommended by the Health Protection Agency, now part of Public Health England. New evidence is presented which show that comforter and carer radiation exposure levels from paediatric molecular radiotherapy in routine clinical practice are acceptably low. Pediatr Blood Cancer 2015;62:235-239.
© 2014 Wiley Periodicals, Inc. © 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  comforters and carers; molecular radiotherapy; neuroblastoma; radiation exposure; thyroid cancer

Mesh:

Year:  2014        PMID: 25284346     DOI: 10.1002/pbc.25250

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  4 in total

1.  Feasibility of Administering High-Dose (131) I-MIBG Therapy to Children with High-Risk Neuroblastoma Without Lead-Lined Rooms.

Authors:  Bae P Chu; Christopher Horan; Ellen Basu; Lawrence Dauer; Matthew Williamson; Jorge A Carrasquillo; Neeta Pandit-Taskar; Shakeel Modak
Journal:  Pediatr Blood Cancer       Date:  2016-01-15       Impact factor: 3.167

2.  Phase I/II study of (131)I-MIBG with vincristine and 5 days of irinotecan for advanced neuroblastoma.

Authors:  S G DuBois; S Allen; M Bent; J F Hilton; F Hollinger; R Hawkins; J Courtier; Y P Mosse; K K Matthay
Journal:  Br J Cancer       Date:  2015-01-20       Impact factor: 7.640

3.  Application of a tungsten apron for occupational radiation exposure in nursing care of children with neuroblastoma during 131I-meta-iodo-benzyl-guanidine therapy.

Authors:  Yuka Taniguchi; Hiroshi Wakabayashi; Hiroto Yoneyama; Zhuoqing Chen; Kei Morino; Akiko Otosaki; Masako Yamada; Anri Inaki; Daiki Kayano; Seigo Kinuya
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

4.  A Phase II Trial of a Personalized, Dose-Intense Administration Schedule of 177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-Risk Neuroblastoma-LuDO-N.

Authors:  Fredrik Sundquist; Kleopatra Georgantzi; Kirsten Brunsvig Jarvis; Jesper Brok; Minna Koskenvuo; Jelena Rascon; Max van Noesel; Per Grybäck; Joachim Nilsson; Arthur Braat; Mikael Sundin; Sandra Wessman; Nikolas Herold; Lars Hjorth; Per Kogner; Dan Granberg; Mark Gaze; Jakob Stenman
Journal:  Front Pediatr       Date:  2022-03-10       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.